Amdocs (NASDAQ:DOX – Get Free Report) will likely be releasing its Q1 2026 results after the market closes on Tuesday, February 3rd. Analysts expect Amdocs to post earnings of $1.75 per share and revenue of $1.1534 billion for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, February 4, 2026 at 4:00 PM ET.
Amdocs Stock Up 0.9%
DOX stock opened at $83.43 on Tuesday. The stock has a market cap of $9.01 billion, a PE ratio of 16.52, a price-to-earnings-growth ratio of 1.40 and a beta of 0.40. The firm’s 50-day simple moving average is $79.81 and its 200 day simple moving average is $82.99. Amdocs has a fifty-two week low of $74.32 and a fifty-two week high of $95.41. The company has a quick ratio of 1.17, a current ratio of 1.17 and a debt-to-equity ratio of 0.23.
Amdocs Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Wednesday, December 31st will be paid a dividend of $0.527 per share. The ex-dividend date of this dividend is Wednesday, December 31st. This represents a $2.11 annualized dividend and a yield of 2.5%. Amdocs’s dividend payout ratio (DPR) is presently 41.78%.
Wall Street Analyst Weigh In
Read Our Latest Analysis on DOX
Hedge Funds Weigh In On Amdocs
Hedge funds and other institutional investors have recently made changes to their positions in the company. Amundi lifted its holdings in Amdocs by 73.0% during the 1st quarter. Amundi now owns 13,778 shares of the technology company’s stock worth $1,217,000 after buying an additional 5,816 shares during the period. Millennium Management LLC raised its position in shares of Amdocs by 458.3% during the first quarter. Millennium Management LLC now owns 67,047 shares of the technology company’s stock worth $6,135,000 after acquiring an additional 55,038 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Amdocs by 12.6% in the first quarter. Goldman Sachs Group Inc. now owns 331,146 shares of the technology company’s stock worth $30,300,000 after acquiring an additional 37,087 shares during the period. Empowered Funds LLC boosted its holdings in Amdocs by 12.0% in the first quarter. Empowered Funds LLC now owns 15,979 shares of the technology company’s stock valued at $1,462,000 after acquiring an additional 1,709 shares during the last quarter. Finally, Jane Street Group LLC increased its position in Amdocs by 195.4% during the 1st quarter. Jane Street Group LLC now owns 115,929 shares of the technology company’s stock valued at $10,608,000 after purchasing an additional 76,683 shares during the period. 92.02% of the stock is currently owned by institutional investors and hedge funds.
Amdocs Company Profile
Amdocs (NASDAQ: DOX) is a global software and services provider specializing in solutions for communications, media and entertainment companies. The company designs, develops and integrates revenue management, customer experience and digital services platforms that enable service providers to launch and monetize new offerings, streamline operations and enhance subscriber engagement. Amdocs’ product suite encompasses billing and order management, customer relationship management, digital commerce and network function virtualization, supported by professional services for implementation, integration and managed operations.
Founded in 1982 and structured as a separate public company in 1998, Amdocs has its corporate headquarters in Chesterfield, Missouri, and maintains major development centers in Ra’anana, Israel.
Featured Articles
- Five stocks we like better than Amdocs
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Do not delete, read immediately
- The $100 Trillion AI Story No One Is Telling You
- NEW LAW: Congress Approves Setup For Digital Dollar?
- If You Keep Cash In A U.S. Bank Account… Read This NOW
Receive News & Ratings for Amdocs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amdocs and related companies with MarketBeat.com's FREE daily email newsletter.
